Key Points - Tesla's Full Self-Driving (FSD) feature is being promoted in a controversial manner, as a doctor recommended a visually impaired 71-year-old patient to use it, raising safety concerns about its L2 classification [4][5] - A major gaming company reported a significant loss of 1.477 billion yuan due to the failure of a self-developed game, leading to a drastic reduction in workforce from 710 to 260 employees [8][9] - BAIC Blue Valley has undergone a leadership change with new appointments, while also reporting a significant increase in vehicle sales for 2025, although it continues to face substantial losses [11][12] - Moore Threads secured a contract worth 660 million yuan, indicating its growing presence in the GPU market and successful delivery capabilities [16][17] - BYD expressed confidence in exceeding its 2026 export target of 1.5 million vehicles by 15%, supported by strong overseas sales [24] - iQIYI has submitted a listing application to the Hong Kong Stock Exchange, part of a broader trend of Baidu-affiliated companies seeking to go public [56][57] - Nokia announced plans to cut approximately 4,100 jobs globally to restructure and address challenges in the telecommunications market [50][51]

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook compared to the overall market performance [56]. Core Insights - The report highlights that 2025 will see concentrated performance releases across the overseas pharmaceutical sector, with companies like Kelun-Biotech, WuXi AppTec, and Fuhong Hanlin showing significant revenue growth and expanding product pipelines [2][12][15]. - Kelun-Biotech's revenue increased by 6.5% to 2.06 billion CNY, while its product sales surged by 949.8% to 543 million CNY, indicating strong market traction [7][8]. - WuXi AppTec reported a robust revenue growth of 46.7% to 5.94 billion CNY, driven by increased capacity utilization and operational efficiency [12][13]. - Fuhong Hanlin's revenue grew by 16.5% to 6.67 billion CNY, with a notable increase in R&D expenses, reflecting a commitment to innovation [15][16]. Summary by Sections Overseas Pharmaceuticals - The report notes that the Hang Seng Healthcare Index fell by 3.23%, underperforming the Hang Seng Index by 0.70 percentage points [6]. - Kelun-Biotech's core pipeline, Sac-TMT, is progressing well overseas, with multiple key clinical trials initiated [9][10]. - WuXi AppTec's market share increased from 21.7% in 2024 to over 24% in 2025, with a significant rise in unfulfilled orders [13][14]. Fuhong Hanlin - Fuhong Hanlin's global product revenue reached 5.82 billion CNY, with overseas sales exceeding 2 billion CNY, reflecting a strong international presence [15][16]. - The company is actively advancing clinical development for its innovative products, including HLX43 and HLX22, which target various cancers [16][17]. Investment Recommendations - The report suggests focusing on companies like Kelun-Biotech and WuXi AppTec due to their strong growth trajectories and expanding product lines [29]. - It also highlights the potential of Fuhong Hanlin's innovative pipeline and its commitment to R&D as key factors for future growth [15][16].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 東方甄選控股有限公司 呈交日期： 2026年3月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 01797 | 說明 | | | | | | | | 多櫃檯證券代號 | | | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | | 已發行股 ...

Summary of Key Points from Conference Call Records Industry Overview - The consumer sector, particularly the cyclical consumption segment, is showing signs of bottoming out, with potential for rebound or reversal in demand. This is supported by positive trends in the restaurant industry, which serves as a key reference point [2][2] - The restaurant industry is experiencing a slowdown in price wars, with companies like McDonald's and KFC implementing slight price increases, indicating a more rational pricing environment [2][2] Company-Specific Insights Haidilao - Haidilao's table turnover rate has improved to over 4.0, with expectations for 2026 revenue to reach approximately 4.6 billion yuan [1][5] - The return of founder Zhang Yong as CEO is expected to accelerate the growth of the main brand and the "hard bone" sub-brands, with plans to expand into lower-tier cities and introduce new dining formats [6][6] - If Haidilao maintains a turnover rate above 4.0 and a customer price close to 100 yuan, it could achieve a profit recovery to around 4.6 billion yuan, corresponding to a valuation of about 20 times [6][6] Mixue Ice Cream - Mixue Ice Cream is expected to see over 20% growth in store openings in 2026, with its price advantage under 10 yuan becoming more pronounced as delivery subsidies decline [1][7] - Despite market concerns about same-store sales and growth, Mixue's actual performance may exceed pessimistic expectations, with a stable same-store sales growth forecast [7][8] Songcheng Performance - Songcheng Performance is projected to achieve revenue between 1 billion to 1.1 billion yuan in 2026, driven by improvements in existing projects and new developments [3][4] Old Puhuang Gold - Old Puhuang Gold is transitioning towards a luxury goods model, with expected revenue of around 7.2 billion yuan in 2026 and a low valuation of 15 times [1][10] - The company is focusing on high-value customers, with significant growth potential in its high-end gold product offerings [11][11] China Oriental Education - China Oriental Education has seen a year-on-year increase of over 25% in spring recruitment collections, with a projected profit of 1 billion yuan for 2026 [1][17] - The company is expanding into new sectors such as beauty and pet care, indicating a strategic diversification [17][18] Dongfang Zhenxuan - Dongfang Zhenxuan is experiencing a fundamental turnaround, with plans to expand its self-operated product offerings by 90% to approximately 1,500 SKUs in the 2026 fiscal year [1][18] - The company is enhancing its multi-channel strategy, including expanding its own app and offline teaching networks [18][18] Bluko - Bluko is guiding for a 30% revenue growth in 2026, with a focus on international expansion and new product categories like building vehicles [1][16] - The company aims for a 70%-80% growth in its overseas segment, leveraging popular IPs for market penetration [16][16] Additional Insights - The overall sentiment in the cyclical consumption sector is cautiously optimistic, with signs of recovery in consumer spending and strategic shifts among key players [2][2] - Companies are increasingly focusing on enhancing customer experience and product offerings to drive sales growth in a competitive environment [1][1]

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook compared to the overall market performance [6][11]. Core Insights - Recent adjustments to the Hong Kong Stock Connect list include companies like Weili Zhibo and Jinfang Pharmaceutical, effective from March 9, 2026. Additionally, Kangfang Biotech's first tri-antibody has received clinical trial approval [2][3]. - Kingsray Biotech expects an adjusted net profit of USD 207-242 million for 2025, representing a year-on-year growth of approximately 246.5%-304.3%, primarily driven by licensing revenue growth from USD 2.4 million in 2024 to USD 256-299 million [2][7]. - The Hang Seng Healthcare Index rose by 2.58%, outperforming the Hang Seng Index by 1.02 percentage points [6]. Summary by Sections 1. Overseas Pharmaceuticals - Companies like Weili Zhibo and Jinfang Pharmaceutical have been included in the Hong Kong Stock Connect list, effective March 9, 2026. Kangfang Biotech's AK150 has received clinical trial approval for treating advanced malignant solid tumors [3][8]. - Songli Pharmaceutical's small molecule GLP-1R agonist ASC30 achieved statistically significant weight loss results in a U.S. Phase II trial, with an average weight reduction of 7.5% after three monthly doses [3][8]. 2. Performance Updates - Kingsray Biotech anticipates a significant increase in net profit for 2025, while Lepu Biotech expects to achieve a net profit of no less than RMB 200 million, marking a turnaround from losses [2][7]. - Jike Si's revenue is projected to decline by 65.6% in 2025, with a net loss of RMB 146 million [2][7]. 3. Recommendations - The report suggests focusing on innovative drugs with ongoing commercialization and business development opportunities, particularly companies like Baijie Shenzhou, Xinda Biotech, and Kangfang Biotech [11]. - In the pharmaceutical sector, companies like Sanofi and China Biopharmaceutical are highlighted for their progressive innovation pipelines [11]. 4. Overseas Education - The education index increased by 3.1%, outperforming the Hang Seng China Enterprises Index by 0.3 percentage points [13]. - The report recommends focusing on Chinese Oriental Education, which is expected to see accelerated enrollment growth due to rising demand for vocational training [15]. 5. Overseas Social Services - Macau's total visitor numbers during the Spring Festival reached a record high, with 1.554 million visitors and an average daily visitor count of 173,000, reflecting a year-on-year growth of 5.5% [17].

Investment Rating - The industry investment rating is "Overweight" indicating that the industry is expected to outperform the overall market [2][6]. Core Insights - Recent adjustments to the Hong Kong Stock Connect list include companies such as Weili Zhibo and Jinfang Pharmaceutical, effective from March 9. Kangfang Biologics has received clinical approval for its first tri-antibody [2][3]. - Kingsray Biotech anticipates an adjusted net profit of USD 207-242 million for 2025, representing a year-on-year growth of approximately 246.5%-304.3%, primarily due to licensing revenue increasing from USD 2.4 million in 2024 to USD 256-299 million [2][7]. - The Hang Seng Healthcare Index rose by 2.58%, outperforming the Hang Seng Index by 1.02 percentage points [6]. Summary by Sections 1. Overseas Pharmaceuticals - Companies like Weili Zhibo, Jinfang Pharmaceutical, and others have been included in the Hong Kong Stock Connect list since March 9. Kangfang Biologics' AK150 has received clinical trial approval for treating advanced malignant solid tumors [3][8]. - Alnylam has initiated a clinical trial for ALN-2232 (ALK7 siRNA) aimed at obesity, with an expected completion date in March 2028 [4][9]. - Agilent Technologies has agreed to acquire Biocare Medical for USD 950 million, enhancing its capabilities in clinical pathology [4][9]. 2. Performance Updates - Kingsray Biotech expects a significant increase in net profit for 2025, while Lepu Biotech anticipates a net profit of no less than RMB 200 million, marking a turnaround [7][8]. - The revenue forecast for Jike Si is projected to decline by 65.6% in 2025, with a net loss of RMB 146 million [7][8]. 3. Recommendations - Focus on innovative drugs with ongoing commercialization and active overseas transactions, particularly companies like BeiGene, Innovent Biologics, and Kangfang Biologics [12]. - In the Pharma sector, companies like 3SBio and Hansoh Pharmaceutical are making strides in their innovative pipelines [12]. 4. Education Sector - The education index increased by 3.1%, outperforming the Hang Seng Index by 0.3 percentage points [14]. - China Oriental Education is recommended due to its strong growth prospects and strategic adjustments in response to vocational training demand [17]. 5. Social Services - Macau's visitor numbers during the Spring Festival reached historical highs, with total inbound travelers at 1.554 million and an average daily visitor count of 173,000, reflecting a year-on-year growth of 5.5% [19].

Group 1 - The report highlights the strong performance of the wind power hydraulic lubrication leader, Chuanrun Co., which is advancing into AIDC liquid cooling, benefiting from the rising industry demand [4] - The company has a solid global layout in high-end energy equipment manufacturing, focusing on offshore wind power and liquid cooling, with overseas revenue reaching 43.64 million yuan in the first half of 2025, a year-on-year increase of 375.7% [4] - The liquid cooling technology is expected to gain traction due to stricter energy consumption regulations for data centers, with NVIDIA's next-generation Rubin chip adopting a fully liquid cooling solution, enhancing market potential [5][6] Group 2 - The asset allocation report emphasizes the continuity of the policy framework for 2026, with a focus on expanding domestic demand and managing financial risks in real estate and local debts [8][9] - The macroeconomic environment is supported by a strong fiscal policy and moderate monetary easing, which is expected to stabilize the equity market [9] - The report outlines a shift towards more execution-oriented industrial policies, enhancing visibility for commercial applications and orders in various sectors [9] Group 3 - The AI demand is projected to exceed expectations, with Shengquan Group positioned to benefit from the high-performance resin market, which is expected to see rapid growth [11] - The company is the largest domestic supplier of electronic chemical materials, with a comprehensive product matrix for high-frequency and high-speed copper-clad laminates [12] - Shengquan Group is expanding its production capacity with new projects set to come online in 2026, including 2000 tons/year of PPO/OPE resin and 1500 tons/year of hydrocarbon resin [12] Group 4 - The automotive industry report discusses the competitive landscape of Robotaxi in the US and China, highlighting Waymo and Tesla as key players in the US market [16][17] - In China, companies like Pony.ai and WeRide are leading the Robotaxi sector, with significant advancements in operational areas and regulatory support for autonomous driving [18] - The report suggests investment opportunities in leading Robotaxi companies and related technologies, emphasizing the acceleration of commercialization in both markets [19] Group 5 - The macroeconomic commentary on the government work report for 2026 outlines a growth target of 4.5%-5%, with a focus on expanding domestic demand and optimizing supply [20][22] - The report emphasizes the importance of employment, with a target of over 12 million new urban jobs, aligning with the economic growth objectives [23] - The fiscal policy remains proactive, with a projected budget expenditure of 30 trillion yuan for 2026, reflecting a commitment to sustainable growth [25][26] Group 6 - The report indicates a strong emphasis on technology innovation as a driver for new economic momentum, with significant increases in R&D investment expected [36][37] - The focus on high-level self-reliance in technology is set to support the development of new industries and enhance the digital economy's contribution to GDP [37][38] - The report outlines plans for substantial investments in modernizing the industrial system, with a focus on high-quality development and technological advancements [38]

Investment Rating - The report indicates a positive outlook for the overseas pharmaceutical industry, particularly highlighting the collaboration between China National Pharmaceutical Group (中生) and Sanofi on JAK/ROCK inhibitors, and the approval of a new indication for Innovent Biologics' BTK inhibitor in China [1][4][6]. Core Insights - The report emphasizes significant revenue growth projections for companies such as Crystal Holding, which anticipates revenue of at least 780 million RMB in 2025, representing a year-on-year increase of approximately 193%. Additionally, He Yu expects revenue of 612 million RMB, a 21% increase year-on-year [5][6]. - The collaboration between China National Pharmaceutical Group and Sanofi is expected to yield a total of 1.35 billion USD in upfront payments and potential milestone payments of up to 1.395 billion USD for the global development and commercialization of the JAK/ROCK inhibitor [2][6]. - The report also notes that the BTK inhibitor from Innovent Biologics has received approval for a new indication in adult chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients who have undergone prior treatment [2][6]. Summary by Sections 1. Overseas Pharmaceuticals - The report highlights the collaboration between China National Pharmaceutical Group and Sanofi regarding JAK/ROCK inhibitors and the approval of a new indication for Innovent Biologics' BTK inhibitor [1][4][6]. - The healthcare index has seen a decline of 6.24%, underperforming the Hang Seng Index by 2.23 percentage points [4]. 2. Performance Updates - Crystal Holding expects to achieve a revenue of at least 780 million RMB in 2025, with a year-on-year growth of approximately 193%, and a net profit of at least 100 million RMB, marking a turnaround from losses [5]. - He Yu anticipates a revenue of 612 million RMB in 2025, reflecting a 21% year-on-year increase, with a net profit of 55 million RMB, up 95% year-on-year [5]. 3. Key Events - The report discusses the successful Phase III clinical trial of Roche's BTK inhibitor Fenebrutinib for relapsing multiple sclerosis, which has shown statistically significant results [7]. - The FDA has granted priority review status to Priovant Therapeutics' TYK2/JAK1 inhibitor for dermatomyositis, which, if approved, would be the first targeted therapy for this condition [8]. 4. Investment Recommendations - The report suggests focusing on innovative drug companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and others [9]. - It also highlights the ongoing transformation in the pharmaceutical sector, with companies like 3SBio and Hansoh Pharmaceutical making strides in their innovative pipelines [9].

Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook for the sector's performance compared to the overall market [5][10]. Core Insights - The report highlights significant developments in the pharmaceutical sector, including a licensing agreement between China National Pharmaceutical Group (Sinopharm) and Sanofi for the JAK/ROCK inhibitor, and the approval of a new indication for Innovent Biologics' BTK inhibitor in China [1][2]. - Performance forecasts for companies such as Crystal Holding and He Yu indicate substantial revenue growth, with Crystal Holding expected to achieve at least 780 million RMB in revenue for 2025, representing a year-on-year increase of approximately 193% [6][7]. Summary by Sections 1. Overseas Pharmaceuticals - Sinopharm and Sanofi have entered into an exclusive licensing agreement for the global development, production, and commercialization of the JAK/ROCK inhibitor, with potential milestone payments totaling up to 1.395 billion USD [2][7]. - Innovent Biologics' BTK inhibitor, Jiepalit (Pirtobrutinib), has received NMPA approval for a new indication in adult patients with chronic lymphocytic leukemia (CLL) who have previously undergone systemic treatment [2][7]. - Roche's BTK inhibitor Fenebrutinib has successfully met primary endpoints in a Phase III trial for relapsing multiple sclerosis, potentially becoming the first effective oral treatment for both relapsing and primary progressive forms of the disease [3][8]. 2. Performance Updates - Crystal Holding anticipates a revenue of no less than 780 million RMB in 2025, with a net profit of at least 100 million RMB, marking a turnaround from losses [6][7]. - He Yu expects to achieve 612 million RMB in revenue for 2025, reflecting a 21% year-on-year growth, with net profit projected at 55 million RMB, a 95% increase [6][7]. 3. Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and others [10]. - It also highlights the importance of monitoring clinical progress in key pipelines for companies transitioning towards innovation [10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has entered a phase of "structural optimization and profit recovery," with an increase in the proportion of self-operated products and multi-channel layout expected to continue improving profitability [11] - The company reported a significant recovery in profitability, with a net profit of 239 million yuan in FY2026H1, compared to a loss of 96.5 million yuan in the same period last year [6][11] - The self-operated product strategy has become a core growth engine, contributing 2 billion yuan in revenue in FY2026H1, representing a year-on-year increase of 18.1% [8] Financial Performance Summary - For FY2026H1, the company achieved revenue of 2.31 billion yuan, a year-on-year increase of 5.7%, with GMV totaling approximately 4.1 billion yuan, reflecting a 16.4% growth after excluding one-time disturbances [6] - The gross profit for FY2026H1 was 840 million yuan, with a gross margin of 36.4%, an increase of 2.8 percentage points year-on-year, driven by an increase in the proportion of self-operated products and improved supply chain efficiency [6] - The company’s operating expenses have stabilized, with sales expense ratio, management expense ratio, and R&D expense ratio at approximately 19%, 3.6%, and 2.3% respectively, showing a significant decrease compared to the previous year [7] Future Projections - The company is projected to achieve revenues of 5.08 billion yuan, 6.05 billion yuan, and 7.19 billion yuan for FY2026, FY2027, and FY2028 respectively, with corresponding net profits of 445.26 million yuan, 528.04 million yuan, and 644.72 million yuan [10][11] - The expected P/E ratios for FY2026, FY2027, and FY2028 are approximately 50.14, 42.28, and 34.63 respectively, indicating a favorable valuation outlook [10][11]